Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the ...

Compounding pharmacies, that produced the weight loss drugs at a fraction of their brand name price, are being forced to stop ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...

Our writer takes a look at three red-hot growth stocks that have more than doubled this year to see if any of them interest him. The post 3 growth stocks that have rocketed more than 100% in 2025!

Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments ...